Maryland residents may be interested in a new drug that could help reduce the effects of cerebral palsy. Researchers working on the development of the drug submitted findings that show there may be an opportunity to treat potential cases of cerebral palsy, even after birth. By utilizing an anti-inflammatory drug that uses nanomolecules, the drug is able to target the exact locations where it is needed. Doctors hope that the inflammation, which can lead to cerebral palsy, will be significantly reduced with the aid of this drug. The study has yet to be tested on humans and no study has been done on the potential long-term consequences of the drug's use.
This news is of particular significance considering the likelihood an infant is born with cerebral palsy is as much as one in every 300 children, according to the Center for Disease Control and Prevention. Cerebral palsy often occurs as the result of a birth injury in cases of medical malpractice. A bacterial infection in the womb and umbilical cord complications are also common causes of cerebral palsy.
In cases where complications occur during childbirth, medical professionals are required to take immediate action to ensure that the infant is not harmed. If a doctor fails to take the adequate steps to ensure the newborn's wellbeing, they may be held liable for the consequences.
The improper handling of childbirth may also be classified as medical malpractice. When medical professionals make mistakes, they may be held financially responsible for short and long term medical costs and the loss of the quality of life, amongst other possible consequences. This could potentially include needing to pay for long-term care for any child disabled by a medical injury.